MGMT and pancreatic neuroendocrine tumor: Moreover, the first large prospective phase II study of TEM in patients with advanced pancreatic neuroendocrine tumors, ECOG‐ACRIN E2211, showed that a lack of MGMT expression by IHC was associated with a superior overall response rate, irrespective of treatment with either TEM or CAPTEM [5].